Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 10/20 | 0.53 |
| ▸ | GNAO1 | P09471 | 10/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 10/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240682 | 0.85 | CHRM3 (0.44) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL1048005 | 0.83 | GPR183 (0.47) | GNAI3GNAO1GNAI1KCNH2KDM4E | |
| SCHEMBL4474282 | 0.82 | SMN1; SMN2 (0.50) | GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL17212830 | 0.77 | GNAO1 (0.63) | GNAI3GNAO1GNAI1 | |
| SCHEMBL1936310 | 0.77 | HSD11B1 (0.37) | GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL29086855 | 0.77 | GNAI3 (0.53) | GNAI3GNAO1GNAI1KCNH2CHRM3 | |
| SCHEMBL6944812 | 0.77 | KCNH2 (0.55) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL2527190 | 0.76 | S1PR1 (0.46) | ALDH1A1CHRM3 | |
| Acetic Acid SCHEMBL4538190 | 0.75 | POLB (0.49) | GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL8309136 | 0.74 | HSD11B1 (0.36) | GNAI3GNAO1GNAI1EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | GNAI3 472/4885GNAO1 290/4885GNAI1 451/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | GNAI3 472/4885GNAO1 290/4885GNAI1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.